Prescriber Criteria Form

Venclexta 2024 PA Fax 1353-A v1 010124.docx Venclexta (venetoclax) Coverage Determination

This fax machine is located in a secure location as required by HIPAA regulations.

Complete/review information, sign and date. Fax signed forms to CVS Caremark at **1-855-633-7673**.

Please contact CVS Caremark at **1-866-785-5714** with questions regarding the prior authorization process.

When conditions are met, we will authorize the coverage of Venclexta (venetoclax).

Drug Name:			
Venclexta (venetoclax)			
Patient Name:			
Patient ID:			
Patient DOB:	Patient Phone:		
Prescriber Name:	•		
Prescriber Address:			
City:	State:	Zip:	
Prescriber Phone:	Prescriber Fax:		
Diagnosis:	ICD Code(s):		
	•		
Please circle the appropriate ans	wer for each guestion.		

Pleas	se circle the appropriate answer for each question.		
1	Does the patient have a diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)? [If yes, then no further questions.]	Yes	No
2	Does the patient have a diagnosis of mantle cell lymphoma? [If yes, then no further questions.]	Yes	No
3	Does the patient have a diagnosis of acute myeloid leukemia (AML)? [If no, then skip to question 8.]	Yes	No
4	Is the patient 60 years of age or older? [If yes, then no further questions.]	Yes	No
5	Is the patient less than 60 years of age and has unfavorable risk genetics and a TP53-mutation? [If yes, then no further questions.]	Yes	No
6	Does the patient have comorbidities that preclude the use of intensive induction chemotherapy? [If yes, then no further questions.]	Yes	No
7	Will the requested drug be used for relapsed or refractory disease? [No further questions.]	Yes	No

8	Does the patient have a diagnosis of blastic plasmacytoid dendritic cell neoplasm (BPDCN)?		No
	[If no, then skip to question 11.]		
9	Does the patient have systemic disease which is being treated with palliative intent? [If yes, then no further questions.]	Yes	No
10	Does the patient have relapsed or refractory disease? [No further questions.]		No
11	Does the patient have a diagnosis of multiple myeloma? [If no, then skip to question 15.]	Yes	No
12	Is the disease relapsed or progressive? [If no, then no further questions.]	Yes	No
13	Will the requested drug be used in combination with dexamethasone? [If no, then no further questions.]	Yes	No
14	Does the patient have a t(11:14) translocation? [No further questions.]	Yes	No
15	Does the patient have a diagnosis of Waldenstrom macroglobulinemia/lymphoplasmacytic lymphoma? [If no, then skip to question 18.]	Yes	No
16	Does the patient have previously treated disease that did not respond to primary therapy? [If yes, then no further questions.]	Yes	No
17	Does the patient have progressive or relapsed disease? [No further questions.]	Yes	No
18	Does the patient have a diagnosis of systemic light chain amyloidosis? [If no, then skip to question 20.]	Yes	No
19	Does the patient have relapsed or refractory disease with a t(11:14) translocation? [No further questions.]	Yes	No
20	Does the patient have a diagnosis of myelodysplastic syndrome?	Yes	No
			•
Commo	ents:		
	<u> </u>		
	ning this form, I attest that the information provided is accurate and true as of this date and that entation supporting this information is available for review if requested by the health plan.	t the	

Date:_____

Prescriber (or Authorized) Signature: